- PAVmed Inc (NASDAQ:PAVM) announced the successful implantation of its PortIO Intraosseous Infusion System in three patients as part of a first-in-human (FIH) clinical study of up to 40 patients.
- No complications have occurred. "This is a groundbreaking milestone in the field of vascular access," said implanting interventional radiologist, Dr. David Sabbag.
- PortIO is an implantable intraosseous vascular access device designed for long-term use and to eliminate many of the shortcomings of existing vascular access devices, including the need for regular flushing to maintain patency.
- The PortIO Intraosseous Infusion System consists of an implantable intraosseous vascular access device and insertion kit.
- PortIO can be inserted and removed near-percutaneously without requiring a surgical pocket or significant dissection and does not require confirmation of the position of the tip by x-ray or other means.
- Price Action: PAVM shares are up 25.4% at $1.58 during the market session on the last check Thursday.
